



*United States
Nuclear Regulatory Commission*

**RULEMAKING ISSUES
RADIOLOGICAL CRITERIA FOR
LICENSE TERMINATION**

March 26, 1996

*John E. Glenn
Office of Nuclear Regulatory Research
U.S. Nuclear Regulatory Commission
Washington, D.C. 20555*



Background

- ✓ Published proposed rule for comment - 8/94
- ✓ Workshop on SSABs - 12/94
 - NUREG/CR-6307 - 6/95
- ✓ Public comment period closed - 1/95
 - NUREG/CR-6353 - 10/95
- ✓ Extended rule schedule - 8/95
- ✓ Workshop on implementation of rule - 9/95



Overview of Public Comments

✓ 101 different commenters

- government agencies
- licensees
- public groups
- industry groups
- Native American organizations
- individuals

✓ General reactions varied

- agreement/disagreement on provisions, e.g., restricted use
- disagreement for differing reasons on provisions, e.g., 15 mrem



§20.1402(b) 15 mrem/y

- ✓ Agree with 15
- ✓ Disagree with 15 -
 - too high - return to background preferred
 - too low, - 25-100 mrem/y with ALARA preferred
- ✓ Issues on both sides
 - health impacts
 - costs vs impacts
 - ability to measure such low doses
 - relationship with background
 - effects on disposal capacity
 - consistency with other standards



§20.1402(c) ALARA

- ✓ Require ALARA analysis to assess doses < 15 mrem/y
- ✓ Don't require ALARA analysis < 15 mrem/y
 - large costs
 - small reduction in risk
- ✓ Allow ALARA analysis to move standard > 15 mrem/y
- ✓ Don't permit ALARA > 15 mrem/y



§20.1402(d) Restricted Release

✓ Agree

- ▶ allows consideration of realistic land uses, protects public health and permits flexibility
- ▶ rely on institutional controls - don't assume eventual failure
- ▶ should be allowed if ALARA or if under continuous owner control as in further industrial use

✓ Disagree

- ▶ institutional controls uncertain, can't be enforced indefinitely or can become ineffective
- ▶ no responsible regulatory oversight

✓ Suggest possible Federal ownership or legislative solutions

- incorporating assessment of the robustness of risk of cancer mortality in the Registry of Radiation Workers. *J. Radiol. Prot.* **13**, 95-108 (1993).
49. J. Cuzick. Radiation-induced myelomatosis. *N. Engl. J. Med.* **304**, 204-210 (1981).
50. T. Ishimaru, M. Otake and M. Ichimaru. Dose-response relationship of neutrons and gamma rays to leukemia incidence among atomic bomb survivors in Hiroshima and Nagasaki by type of leukemia, 1950-1971. *Radiat. Res.* **77**, 377-394 (1979).
51. D. L. Preston, S. Kusumi, M. Tomonaga, S. Izumi, E. Ron, A. Kuramoto, N. Kamada, H. Dohy, T. Matsui, H. Nonaka, D. E. Thompson, M. Soda and K. Mabuchi. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. *Radiat. Res.* **137**, S68-S97 (1994).
52. C. Rooney, V. Beral, N. Maconochie, P. Fraser and G. Davies. Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority. *Br. Med. J.* **307**, 1391-1397 (1993).
53. A. M. Stewart and G. W. Kneale. A-bomb radiation and evidence of late effects other than cancer. *Health Phys.* **58**, 729-735 (1990).